New drug for treatment of multiple sclerosis developed in Russia

7 March 2017

A new drug for the treatment of multiple sclerosis has recently been developed in Russia, according to an official spokesman for Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent.

It is reported that the new drug, will be produced by Pharmasyntez, one of Russia’s leading drugmakers in cooperation with the Russian Institute of Bioorganic Chemistry, is currently the subject of clinical studies and will appear on the market after 2020.

Details of the new MS drug were not revealed, but back in April 2016 public records showed that Pharmasyntez had reported safety and efficacy data from a Phase IIa trial of Xemys, a CD antigen modulator, for the treatment of MS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK